Prof. Chan Cheah
*52 – EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort
64 – Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial
*226 – Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study
665 – Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
793 – MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101
884 – Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study
**1016 – Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial
*1839 – CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies
1910 – Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a nextgeneration BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma
1960 – Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up
2115 – Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up
3570 – Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study
*3578 – Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial
3583 – Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe101 study
3584 – Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe101 study
3601 – Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation
*3614 – SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma
*3747 – SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma
3889 – Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report
3890 – Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101
**3891 – Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study
5338 – An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma
5352 – Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5- year follow-up of a pivotal Phase II study
*5511 – Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response
5513 – Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term followup results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma
5524 – A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) Tcell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)
*First Author
**Last Author
